Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis

BMJ Open Respiratory Research

Volumn 4, Issue 1, 2017, Pages

  Hajari Case, Amy ^a   Johnson, Peace ^a  

^a Division of Pulmonary Allergy Critical Care and Sleep Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDIARRHEAL AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FIBROBLAST GROWTH FACTOR RECEPTOR; NINTEDANIB; PIRFENIDONE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ARTERIAL OXYGEN SATURATION; ARTICLE; ASTHENIA; BRONCHIECTASIS; BRONCHITIS; COMPUTER ASSISTED TOMOGRAPHY; CONTUSION; COUGHING; DECREASED APPETITE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EMPHYSEMA; EPISTAXIS; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HEART INFARCTION; HUMAN; HYPOXEMIA; INTERSTITIAL PNEUMONIA; ISCHEMIC HEART DISEASE; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG TRANSPLANTATION; MORTALITY; NAUSEA; PATIENT EDUCATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POSTMARKETING SURVEILLANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY OF LIFE; RHINOPHARYNGITIS; TREATMENT FAILURE; VOMITING;

EID: 85021683731     PISSN: None     EISSN: 20524439     Source Type: Journal    
DOI: 10.1136/bmjresp-2017-000192     Document Type: Article

References (49)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
2. Yount SE, Beaumont JL, Chen S-Y, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. Lung 2016;194:227-234.
3. Raghu G, Chen SY, Hou Q, et al. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old. Eur Respir J 2016;48:179-86.
4. Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. an International Working Group Report. Am J Respir Crit Care Med 2016;194:265-75.
5. Collard HR, Ward AJ, Lanes S, et al. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ 2012;15:829-35.
6. Boehringer Ingelheim. OFEV (nintedanib) Summary of Product Characteristics. 2016. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003821/WC500182474. pdf. (accessed Sep 2016).
7. Boehringer Ingelheim Pharmaceuticals, Inc. OFEV (nintedanib) prescribing information. 2016. www.accessdata.fda.gov/drugsatfda_docs/label/2016/205832s001lbl.pdf. (accessed Sep 2016).
8. Genentech, Inc. ESBRIET® (pirfenidone) prescribing information. 2016. www.gene.com/download/pdf/esbriet_prescribing.pdf. (accessed Sep 2016).
9. Roche Registration Limited. Esbriet (pirfenidone) Summary of Product Characteristics. 2016. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002154/WC500103049.pdf. (accessed Sep 2016).
10. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2015;192:e3-e19.
11. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-82.
12. Hostettler KE, Zhong J, Papakonstantinou E, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res 2014;15:157.
13. Grimminger F, Günther A, Vancheri C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1426-33.
14. Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and antiinflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 2014;349:209-20.
15. Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1434-45.
16. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-87.
17. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 20142071;370:2071-82;37082:2071-82.
18. Corte T, Bonella F, Crestani B, et al. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res 2015;16:116.
19. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:830-6.
20. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011;184:1382-9.
21. Bonella F, Stowasser S, Wollin L. Idiopathic pulmonary fibrosis:current treatment options and critical appraisal of nintedanib. Drug Des Devel Ther 2015;9:6407-19.
22. Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 2016;193:178-85.
23. Ryerson CJ, Kolb M, Richeldi L, et al. Effect of baseline GAP index stage on decline in lung function with nintedanib in patients with idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med 2016;193:A2691.
24. Maher TM, Flaherty KR, Inoue Y, et al. No effect of baseline diffusing capacity of lung for carbon monoxide on benefit of nintedanib. Eur Respir J 2016;48:OA4959.
25. Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 2017;72:340.
26. Taniguchi H, Xu Z, Azuma A, et al. Subgroup analysis of Asian patients in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Respirology 2016;21:1425-30.
27. Case A, Capapey J, Kimura T, et al. Consistent effect of nintedanib on reducing FVC decline in patients with or without honeycombing in the INPULSIS trials of idiopathic pulmonary fibrosis. Chest 2015;148:361A-361B.
28. Raghu G, Wells AU, Nicholson AG, et al. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med 2017;195:78-85.
29. Jacob J, Hansell DM. HRCT of fibrosing lung disease. Respirology 2015;20:859-72.
30. Kreider ME, Hansen-Flaschen J, Ahmad NN, et al. Complications of video-assisted thoracoscopic lung biopsy in patients with interstitial lung disease. Ann Thorac Surg 2007;83:1140-4.
31. Hutchinson JP, McKeever TM, Fogarty AW, et al. Surgical lung biopsy for the diagnosis of interstitial lung disease in England: 1997-2008. Eur Respir J 2016;48:1453-61.
32. Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials. Respir Med 2016; :74-9.
33. Crestani B, Quaresma M, Kaye M, et al. Long-term treatment with nintedanib in patients with IPF: an update from INPULSIS®-ON [abstract]. Eur Respir J 2016;48:OA4960.
34. Wuyts WA, Kolb M, Stowasser S, et al. First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of ≤50 % of predicted value. Lung 2016;194:739-43.
35. Ikeda S, Sekine A, Baba T, et al. Hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis: a single-center experience. Respir Investig 2017;55:51-4.
36. Bonella F, Kreuter M, Hagmeyer L, et al. Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis. Respiration 2016;92:98-106.
37. Kontou M, Bousgou V, Tzilas V, et al. Clinical experience with nintedanib for the treatment of IPF in 80 cases. Eur Respir J 2016;48:PA2086.
38. Noth I, Allinger A, Kaul M, et al. Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF): one-year data from post-marketing surveillance in the United States. Am J Respir Crit Care Med 2016;193:A2692.
39. Pereira C, Baddini-Martinez JA, Baldi BG, et al. Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil. Arch Bronconeumol 2016;52:92.
40. Roodhart JM, Langenberg MH, Witteveen E, et al. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 2008;3:132-43.
41. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6:465-77.
42. Sampson C, Gill BH, Harrison NK, et al. The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative study. BMC Pulm Med 2015;15:155.
43. Holland AE, Fiore JF, Goh N, et al. Be honest and help me prepare for the future: What people with interstitial lung disease want from education in pulmonary rehabilitation. Chron Respir Dis 2015;12:93-101.
44. Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015;34:1-15.
45. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013;188:e13-e64.
46. Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev 2014;10.
47. Vainshelboim B, Fox BD, Oliveira J, et al. Exercise training in idiopathic pulmonary fibrosis. Expert Rev Respir Med 2016;10:69-77.
48. Bell EC, Cox NS, Goh N, et al. Oxygen therapy for interstitial lung disease: a systematic review. Eur Respir Rev 2017;26:160080.
49. National Institute for Health and Care Excellence (NICE). Idiopathic pulmonary fibrosis in adults. Quality standard (2015). https://www.nice.org.uk/guidance/qs79. (accessed Sep 2016).